Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018536 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.
A Phase 1 study, sponsored by Janssen R&D Ireland.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02018536 is a Phase 1 study that has completed, run by Janssen R&D Ireland. The registered enrollment target is 48 participants.
The verdict
NCT02018536, a Phase 1 study, has completed, sponsored by Janssen R&D Ireland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (what the body does to a medication) of GSK2336805 alone and with the co-administration of TMC435 in healthy Japanese participants.
Interventions
- DRUG GSK2336805 60 mg
- DRUG GSK2336805 30 mg
- DRUG GSK2336805 120 mg
- DRUG TMC435 150 mg (Treatment A)
- DRUG GSK2336805 60 mg (Treatment B and part of Treatment C and D)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02018536
The ClinicalTrials.gov registry entry for NCT02018536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen R&D Ireland, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which GSK2336805 60 mg is the first listed.
NCT02018536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02018536 about?
NCT02018536 is a clinical study titled "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.". The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (what the body does to a medication) of GSK2336805 alone and with the co-administration of TMC435 in healthy Japanese participants.
What is the current status of trial NCT02018536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-10. Estimated completion is 2014-03.
What interventions are being tested in trial NCT02018536?
The interventions under investigation include: GSK2336805 60 mg (DRUG), GSK2336805 30 mg (DRUG), GSK2336805 120 mg (DRUG), TMC435 150 mg (Treatment A) (DRUG), GSK2336805 60 mg (Treatment B and part of Treatment C and D) (DRUG).
Who is sponsoring clinical trial NCT02018536?
This trial is sponsored by Janssen R&D Ireland, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.